Arch Biopartners Arranges Non-Brokered Private Placement

Core Points - Arch Biopartners Inc. announced a non-brokered private placement offering of 225,806 common shares at a price of $1.55 per share, aiming for gross proceeds of$350,000 CAD [1][2] - The proceeds will be utilized for general working capital and expenses not covered by existing funding grants, with the offering set to close on March 6, 2025, pending regulatory approvals [2][3] - All shares issued will have a hold period of four months and one day from the closing date, with finders' fees totaling $13,500 to be paid [3] Company Overview - Arch Biopartners Inc. is focused on late-stage clinical trials aimed at preventing acute kidney injury and organ damage due to inflammation [4] - The company is developing novel drugs targeting the dipeptidase-1 (DPEP1) inflammation pathway, with lead candidates LSALT peptide and cilastatin addressing significant unmet medical needs related to kidney injury [4] - The company has 65,621,366 common shares outstanding [5]